Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma

Autor: Brian K. Link, Eldad J. Dann, Roopesh Kansara, Maja Bech Juul, Gita Thanarajasingam, Adir Shaulov, Umar Farooq, Michael Roost Clausen, Daniel J. Smith, Andrés J.M. Ferreri, Diego Villa, Joseph M. Connors, Michael Gilbertson, Chan Yoon Cheah, Tarec Christoffer El-Galaly, Thomas Stauffer Larsen, Carrie A. Thompson, Martin Hutchings, Inger Lise Gade, John F. Seymour, Neta Goldschmidt, Teresa Calimeri, Kerry J. Savage, Jakob Werner Hansen, Grzegorz S. Nowakowski, Stephen Opat, Mette Dahl Bendtsen, Laurie H. Sehn, Staffan Holmberg, N. George Mikhaeel, Matthew J. Maurer, C. Cecchetti, Tsofia Inbar, Sabrina Cordua

Publikováno v: El-Galaly, T C, Cheah, C Y, Bendtsen, M D, Nowakowski, G S, Kansara, R, Savage, K J, Connors, J M, Sehn, L H, Goldschmidt, N, Shaulov, A, Farooq, U, Link, B K, Ferreri, A J M, Calimeri, T, Cecchetti, C, Dann, E J, Thompson, C A, Inbar, T, Maurer, M J, Gade, I L, Juul, M B, Hansen, J W, Holmberg, S, Larsen, T S, Cordua, S, Mikhaeel, N G, Hutchings, M, Seymour, J F, Clausen, M R, Smith, D, Opat, S, Gilbertson, M, Thanarajasingam, G & Villa, D 2018, ' Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma ', European Journal of Cancer, vol. 93, pp. 57-68 . https://doi.org/10.1016/j.ejca.2018.01.073

PURPOSE: Secondary CNS involvement (SCNS) is a profoundly adverse complication of diffuse large B-cell lymphoma. Evidence from older series indicated a median overall survival (OS) < 6 months; however, data from the immunochemotherapy era are limited

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2b4286ba19f96fcf65520e603491c18
https://pure.au.dk/portal/da/publications/treatment-strategies-outcomes-and-prognostic-factors-in-291-patients-with-secondary-cns-involvement-by-diffuse-large-bcell-lymphoma(f3dacb05-0ad4-4eb4-86b5-eff16e7f2727).html